Dead-cell removal technology


ImmunoSolv is committed to developing reagents and devices that mimic in vitro the efficient dead-cell removal mechanisms that are so important for the health of tissues in vivo, thereby improving the quality of cells in the laboratory.

Importance of dead-cell removal in vivo and in vitro cell populations

Programmed cell death (apoptosis) is a feature of all tissues. Apoptotic cells are swiftly, and in inflammatory terms quietly, removed by phagocytes, a homeostatic process that keeps tissues healthy. Necrotic (dead) cells cause tissue damage. In vitro, the phagocytic clearance mechanism is absent, dead cells persist, and their inhibitory effects lead to sub-optimal cell culture conditions with accumulation of dead cells and debris.

It is well known that, when cells engage their apoptosis ‘suicide’ programme, or when their membranes lose integrity through post-apoptotic necrosis or through primary necrosis caused, for example, by traumatic physical, or noxious chemical stimuli, they lose the phospholipid asymmetry that characterises the plasma membrane of the viable state. Notably, during apoptosis, the anionic phospholipid, phosphatidylserine (PS) that, in viable cells, is located on the inner leaflet of the plasma-membrane bilayer, becomes exposed on the outer leaflet while the membranes retain their integrity, excluding vital dyes such as trypan blue, propidium iodide and ethidium bromide. When the membranes of necrotic cells lose their integrity, they too expose PS that becomes accessible to PS-binding proteins such as annexin V. Annexin V is commonly used to monitor apoptosis in cell suspensions by flow cytometry, but its interaction with exposed PS and the maintenance of its binding requires a binding buffer containing high Ca2+concentration. This has numerous drawbacks, not least of which is the tendency of such Ca2+ levels to induce clumping of cells and the inconvenience of removing cells from their preferred medium.

Dead-Cert

Dead-Cert

Dead-Cert® Nanoparticles for simple, effective dead-cell removal to improve quality, productivity, storage and utility of cell populations

Immunosolv’s antibody-based Dead-Cert® technology has been developed to discriminate viable cells from dead cells, and cell debris in vitro. Using Immunosolv antibodies, together with additional discriminatory molecules coupled to the surface of 250 nm super-paramagnetic nanoparticles, they have developed a simple, yet highly effective dead-cell removal device: Dead-Cert® Nanoparticles. Because of their ability to bind to membrane structures that are not accessible on viable cells - represented by the red symbols in the cartoons - the coated particles are able to bind selectively to apoptotic (dying) as well as necrotic (dead) cells and cell debris.

Dead-Cert

Once bound to non-viable cells and debris, the Dead-Cert® Nanoparticles can be readily removed with the aid of a simple magnet, dragging the unwanted, inhibitory cells and debris with them and leaving the viable cells behind. Because the coated nanoparticles are designed to interact with conserved structures exposed on non-viable cells, they have broad application to multiple cell types across multiple species. A protein-free discriminatory nanoparticle for application under GMP conditions is currently under development.

Dead-Cert

Dead-cell depletion improves cell cultures

Dead cells exert inhibitory effects over their neighbours and this can have far-reaching consequences. In this example, dead-cell removal at the beginning of this culture of hybridoma cells resulted in over 100% improvement in antibody productivity.

Dead-Cert

Immunosolv Dead-Cert® imab6

Dead-Cert® imab6 is used to detect dying cells from the earliest stages of apoptosis to the latest stages of necrosis.

  • Monoclonal antibody
  • No requirement for specialised binding buffers
  • High sensitivity viability assessment from the early stages of apoptosis to the latest stages of necrosis

Dead-Cert

Further literature

Inhibitory effects of persistent apoptotic cells on monoclonal antibody production in vitro: Simple removal of non-viable cells improves antibody productivity by hybridoma cells in culture

mAbs (2009) 1, 370-376

Christopher D. Gregory, John D. Pound, Andrew Devitt, Megan Wilson-Jones, Parthasarathi Ray and Ruth J. Murray